Literature DB >> 26415006

Prevalence and clinical significance of nodular regenerative hyperplasia in liver biopsies.

Sandrine Barge1, Véronique Grando1, Jean-Charles Nault1,2, Chloé Broudin3, Michel Beaugrand1, Nathalie Ganne-Carrié1,2, Dominique Roulot4, Marianne Ziol2,3.   

Abstract

BACKGROUND: Nodular regenerative hyperplasia (NRH) is a rare histological disorder associated with a wide variety of systemic diseases. AIMS: We aimed (i) to report the prevalence of NRH in a database of liver biopsies (LBs) and the frequency of portal hypertension (PHT) at diagnosis, and (ii) to investigate whether associated diseases and/or specific histological lesions, including abnormalities of the microvasculature, were related to PHT.
METHODS: Patients with a histological diagnosis of NRH, referred by seven clinical departments, were retrospectively selected. Clinical, biological, radiological, haemodynamic and endoscopic data at diagnosis were recorded. LBs were reassessed for microvascular abnormalities.
RESULTS: NRH was diagnosed in 4.4% of LBs (n = 159, male: 52%, mean age: 54). Among patients referred for unexplained liver enzyme abnormalities, 15% had NRH. PHT was present at diagnosis in 45 patients (38%), including 13 with portal thrombosis; 65% of patients had an associated disorder. Obliteration of portal vein branches, observed in the LBs of 17 patients (11%), was significantly associated with PHT (P = 0.02). Periportal angiomatosis, observed in 101 patients (63%), was associated with the absence of PHT (P < 10(-4) ).
CONCLUSION: We suggest that NRH is a frequent histological lesion in the setting of unexplained liver enzyme abnormalities. PHT is present at the time of diagnosis in 1/3 of patients regardless of the presence of associated disease. The frequency of periportal angiomatosis in NRH without obliteration of portal vein branches, and its association with the absence of PHT suggest that obstructive portal venopathy would not represent the most frequent mechanism involved in NRH.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  liver biopsy; nodular regenerative hyperplasia; non-cirrhotic portal hypertension; obliterative portal venopathy; periportal angiomatosis

Mesh:

Year:  2015        PMID: 26415006     DOI: 10.1111/liv.12974

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

Review 1.  Pathology of idiopathic non-cirrhotic portal hypertension.

Authors:  Maria Guido; Samantha Sarcognato; Diana Sacchi; Guido Colloredo
Journal:  Virchows Arch       Date:  2018-04-12       Impact factor: 4.064

2.  Nodular regenerative hyperplasia rarely leads to liver transplantation: A 20-year cohort study in all Dutch liver transplant units.

Authors:  Berrie Meijer; Melek Simsek; Hans Blokzijl; Robert A de Man; Minneke J Coenraad; Gerard Dijkstra; Carin Mj van Nieuwkerk; Chris Jj Mulder; Nanne Kh de Boer
Journal:  United European Gastroenterol J       Date:  2016-11-16       Impact factor: 4.623

Review 3.  Interventional Management of Portal Hypertension in Cancer Patients.

Authors:  Max Kabolowsky; Lyndsey Nguyen; Brett E Fortune; Ernesto Santos; Sirish Kishore; Juan C Camacho
Journal:  Curr Oncol Rep       Date:  2022-08-12       Impact factor: 5.945

4.  Portal Cavernoma Mimicking Pancreatic Malignancy.

Authors:  Vivian M Ussui; Lavinia Goldstein; Enrico Souto; Cynthia Levy
Journal:  ACG Case Rep J       Date:  2018-02-28

5.  Portal vein thrombosis leading to pre-sinusoidal non-cirrhotic portal hypertension resulting in decreased synthetic function of the liver.

Authors:  Kevin Kline; Muhannad Al Hanayneh; Mohammad Bilal; Heather Stevenson-Lerner
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019

6.  Paraneoplastic nodular regenerative hyperplasia of the liver associated with placental site trophoblastic tumor.

Authors:  Kathryn Dumas; MaryAnn Wilbur; Jessica Dillon; William Cliby; Carrie Langstraat; Amanda N Fader; Deyin Xing; Rebecca L Stone
Journal:  Gynecol Oncol Rep       Date:  2019-05-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.